ARGENTIS GROUP LTD
Company number 04987966 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Score: B (Good, but pending lab results)
This score reflects a structurally sound and compliant organisation with a long operational history and strong institutional backing. However, like a patient who has forgotten to bring their latest blood test results to an appointment, the absence of filed quantitative financial data (balance sheet, profit & loss) means the core financial vital signs remain opaque. The structural and compliance health is excellent, but the quantitative financial health requires further investigation.
1. Key Vital Signs
- Corporate Pulse (Compliance & Filing Status): Strong & Steady. The company’s accounts and confirmation statements are fully up to date with no overdue filings. This indicates a healthy administrative heartbeat and a business that is breathing smoothly from a regulatory standpoint.
- Medical History (Corporate Longevity & Evolution): Mature & Adapted. Incorporated in 2003, this is a mature patient. The company has undergone significant "evolutionary" changes, transitioning from a PLC (public) to a Private Limited Company, and rebranding from Compass Wealth to Harwood Wealth, and finally to Argentis Group. These historical changes suggest a business that has adapted to its environment rather than succumbing to market diseases.
- Genetic Lineage (Ownership & Control): Robust. The People with Significant Control (PSC) register shows Harwood Capital Management Limited owning 25-50% of shares and voting rights. This indicates strong, concentrated institutional backing—essentially a robust immune system providing strategic support.
- Blood Pressure (Financial Metrics): Unreadable. Because the latest detailed financial figures (turnover, assets, liabilities) are not present in this examination, we cannot measure the financial blood pressure. The share capital stands at a nominal £7.00, which is typical for holding companies where value is stored in reserves rather than allotted shares, but we cannot confirm overall financial circulation without the full accounts.
2. Diagnosis
Condition: Structurally sound, strategically repositioned, but financially opaque.
The patient presents as a healthy, active financial services holding company. The transition from a PLC to a Private Limited Company in 2020, followed by the rebrand to Argentis Group in 2022, suggests the business underwent a deliberate "lifestyle change"—likely moving away from the regulatory and administrative burdens of public status to focus on private, discretionary wealth management.
The recent resignation of name shown to subscribers as both director and secretary in December 2025 could be a minor symptom of internal restructuring, but with a robust board of six remaining directors, there is no immediate sign of corporate arrhythmia. The primary concern is that without the quantitative financial data, we cannot confirm if the business is suffering from silent conditions like shrinking liquidity or accumulated losses. We can only confirm that the outward physical appearance and compliance posture are healthy.
3. Recommendations
To move the patient from a "Good" to an "Excellent" prognosis and ensure long-term financial wellness, the following actions are recommended:
- Complete the Physical Examination: Request and review the latest filed annual accounts at Companies House. It is imperative to examine the "blood work"—specifically the Net Current Assets (working capital) and the P&L Reserve—to ensure the business has healthy cash flow and is not operating with toxic debt levels.
- Monitor Organ Function Post-Resignation: With the recent departure of a key director/secretary, ensure that compliance and administrative duties are seamlessly redistributed among the remaining board to prevent regulatory infection (filing penalties).
- Cardiovascular Check on Subsidiaries: As a holding company (SIC 64205), Argentis Group's health is entirely dependent on the performance of its subsidiaries. Conduct a separate diagnostic on the underlying trading companies to ensure the "heart" is pumping adequate dividends up to the holding company.